← All compounds
peptide93 listings
Semaglutide
GLP-1 Receptor Agonist
FDA-approved GLP-1 agonist. The most-studied weight management peptide.
Weight researchDiabetes researchMetabolic health
/ research index
The research base
Research Maturity
★★★★★
5/5 — Volume of studies
Evidence Strength
★★★★★
5/5 — Quality of evidence
200+ clinical trials. Strongest evidence base for weight research peptides. Works as researched.
/ mechanism of action
How it works
GLP-1 receptor agonist. Decreases appetite, slows gastric emptying, improves insulin sensitivity.
/ research dosing
Common research protocols
Range
0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg/week (FDA titration)
Frequency
Once weekly subcutaneous
Route
Subcutaneous abdomen, thigh, or upper arm
Cycle
Start 0.25mg/week × 4 weeks → 0.5mg/week × 4 weeks → continue escalating monthly to 2.4mg/week target
Research notes
Standard FDA titration schedule for Wegovy. Each dose held minimum 4 weeks before increase. GI side effects (nausea, constipation) most pronounced in first 2 weeks of each new dose. If missing dose: take within 5 days, otherwise skip to next scheduled week.
References
FOR RESEARCH USE ONLY. Doses listed are compiled from published research literature, FDA-approved drug labels, and well-documented research community practice. Not medical advice.
/ standalone use
As a solo compound
Strong standalone evidence. Most clinical trials test it alone.
/ side effects
What to know
Common: nausea (30%), GI adjustment. Usually resolve over time.
/ timeline
Realistic expectations
2-4 weeks for appetite suppression, 12+ weeks for significant changes
/ recommendation
Where to buy Semaglutide
🏆Our pick for Semaglutide
Valor Peptides
5mg · USA · Card / Crypto
- ✓Third-party tested (Janoshik)
- ✓COAs provided — Comprehensive
- ✓Highest verification tier in stock
- ✓4.8★ community rating
Also solid
/ all listings
Full index, price per mg
Supplier
Trust Score
Size
Price
$/mg
Stock
Buy
FOR RESEARCH USE ONLY. Semaglutide is intended for laboratory research and not for human consumption.